Effervescent Pyridoxal-5-Phosphate Formulation for Neonatal Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of pyridoxal-5-phosphate (P5P) for neonatal epilepsy are difficult to administer due to low water solubility, leading to incomplete dose administration and inefficiency in neonatal care, as they form a yellowish solid residue upon dissolution, causing nurse time loss and uncertainty in dosage delivery.
Innovation Solution
An effervescent galenical formulation combining P5P with sodium bicarbonate, which forms a more water-soluble salt (P5PNa), accelerating dissolution through CO2 release and effervescence, improving solubility and administration efficiency, and optionally including pyridoxine hydrochloride and pediatric-friendly excipients like isomalt and colloidal silica.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If P5P is supplied in conventional pharmaceutical formulations, then the active ingredient can be delivered to neonates, but the low water-solubility causes incomplete dissolution and residue formation, leading to incomplete dose administration
Solution Approach 1:
The patent changes the chemical form of P5P from its conventional acid form to a sodium salt form (P5PNa), which fundamentally alters its solubility parameters. This chemical parameter change enables complete dissolution in water without residue formation, ensuring reliable and complete dose administration to neonates
Solution Approach 2:
Sodium bicarbonate serves as an intermediary substance that reacts with P5P to form the more soluble sodium salt. This intermediary facilitates the conversion of insoluble P5P into a soluble form, enabling complete dissolution and accurate dose delivery
2Productivity
If conventional P5P formulations are used, then the treatment can be provided, but the yellowish solid residue on the dissolution device requires additional nurse time for cleanup and verification
Solution Approach 1:
The patent converts the traditionally harmful low-solubility characteristic of P5P into a benefit by forming the sodium salt, which completely dissolves without residue. This eliminates the cleanup burden on nurses while maintaining the therapeutic efficacy of the treatment
3Reliability
If P5P is administered in non-effervescent form, then the formulation is simpler, but the dissolution is slow and incomplete, reducing administration certainty
Solution Approach 1:
The patent utilizes the phase transition from solid to gas through CO2 evolution during the effervescent reaction. This phase transition creates vigorous bubbling that mechanically agitates the dissolution medium, dramatically accelerating the dissolution rate and ensuring complete dissolution of P5PNa
Solution Approach 2:
The effervescent mechanism employs gas generation (CO2 bubbles) to drive the dissolution process. The pneumatic action of evolving gas creates turbulence and enhances mass transfer, ensuring rapid and complete dissolution of the active ingredient
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures complete and rapid dissolution of P5P in water, reducing nurse time and ensuring full dose administration, with improved palatability and stability, as demonstrated by reduced average dilution time and maintained potency over time.
Implementation Method 1
when P5P is brought into contact with sodium bicarbonate, there is formation of a P5PNa salt that is more water-soluble than the acid form (P5P-H)
Implementation Method 2
release of gaseous CO2 shifts the chemical equilibrium of the reaction toward the right. P5P—H+NaHCO3↔P5PNa+H2CO3 H2CO3→H2O+CO2
Implementation Method 3
formation of CO2 bubbles creates effervescence capable of 'stirring' the suspension of powder
Data Source
AI summary
Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate.